Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tubulin tyrosine ligase-like protein 9 (TTLL9) is a probable tubulin polyglutamylase enzyme that generates side chains of glutamate on the gamma-carboxyl group of specific glutamate residues within the C-terminal tail of tubulin proteins[1][5]. This enzymatic modification, known as polyglutamylation, primarily affects microtubule structure and function, contributing to cellular processes such as flagellated sperm motility and the establishment of microtubule heterogeneity, especially within motile cilia[1][5][6]. TTLL9 is most likely functionally active as part of a protein complex, as it lacks some domains necessary for autonomous activity; its closest paralog is TTLL1[1]. Diseases associated with TTLL9 include primary ciliary dyskinesia and urocanase deficiency[1]. TTLL9 is predicted to localize to the cytoplasm, microtubules, and motile cilia, participating in protein modification and cytoskeletal organization[1][6]. No known drugs currently target TTLL9, and there is no indication that TTLL9 is a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tubulin tyrosine ligase-like protein 9 (TTLL9).